Immunotherapy Biomarkers

Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial
Jason J Luke, Katherine Bever, F Stephen Hodi, Janis Taube, Ashish Massey, David Yao, Jaclyn Neely, Rachel Tam, George Lee, Akshita Gupta, Santanu Dutta, Peter Szabo, Riyue Bao, Tim Reilly

Journal for ImmunoTherapy of Cancer May 2025, 13 (5) e011170; DOI: 10.1136/jitc-2024-011170
Tumor location as a risk factor for severe immune-related adverse events
Steven M Blum, Ben Ouyang, Leyre Zubiri, Daniel Leonard, Kamil Slowikowski, Mike Wang, Kelley A Grealish, Nora K Hathaway, Gabriel Molina, Nishi Shah, Donald P Lawrence, Michael Dougan, Alexandra-Chloe Villani, Mari Mino Kendusen, Kerry L Reynolds, Ryan J Sullivan

Journal for ImmunoTherapy of Cancer May 2025, 13 (5) e011312; DOI: 10.1136/jitc-2024-011312
Regional distribution of HLA frequencies in the USA: implications for TCR-based therapies
Christian Roy, Tomasz Sewastianik, Ileana Saenz, Gregory J Opiteck, Sean Stagg, Martin Maiers, Dirk Nagorsen

Journal for ImmunoTherapy of Cancer May 2025, 13 (5) e011441; DOI: 10.1136/jitc-2024-011441
FMO2⁺ cancer-associated fibroblasts sensitize anti-PD-1 therapy in patients with hepatocellular carcinoma
Wenxin Xu, Jialei Weng, Yufei Zhao, Peiyi Xie, Minghao Xu, Shaoqing Liu, Qiang Yu, Mincheng Yu, Bugang Liang, Junbo Chen, Hui-Chuan Sun, Hui Li, Qinghai Ye, Yinghao Shen

Journal for ImmunoTherapy of Cancer May 2025, 13 (5) e011648; DOI: 10.1136/jitc-2025-011648
B4GALT5 inhibits CD8⁺ T-cell response by downregulating MHC-I level through ERAD pathway in PDAC
Xin Xing, Shi-Qi Yin, Xia-Qing Li, Hui Li, Hong-Tai Ma, Aziguli Tulamaiti, Shu-Yu Xiao, Yu-Tong Liu, Hao Zhang, Zhigang Zhang, Yan-Miao Huo, Xiao-Mei Yang, Yan Yang, Xue-Li Zhang

Journal for ImmunoTherapy of Cancer May 2025, 13 (5) e010908; DOI: 10.1136/jitc-2024-010908
Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunotherapy, chemotherapy, or chemoimmunotherapy
Nicole J Toney, Megan T Lynch, Filipa Lynce, Candace Mainor, Claudine Isaacs, Jeffrey Schlom, Renee N Donahue

Journal for ImmunoTherapy of Cancer Apr 2025, 13 (4) e011379; DOI: 10.1136/jitc-2024-011379
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial
Matthew S Block, Garth D Nelson, Jun Chen, Stephen Johnson, Lu Yang, Thomas James Flotte, Eric P Grewal, Robert R McWilliams, Lisa A Kottschade, Evidio Domingo-Musibay, Svetomir N Markovic, Anastasios Dimou, Heather N Montane, Mara A Piltin, Daniel L Price, Samir S Khariwala, Jane Yuet Ching Hui, Courtney L Erskine, Carrie A Strand, David Zahrieh, Haidong Dong, Tina J Hieken

Journal for ImmunoTherapy of Cancer Apr 2025, 13 (4) e011706; DOI: 10.1136/jitc-2025-011706
Siglec-15 antibody–GM-CSF chimera suppresses tumor progression via reprogramming tumor-associated macrophages
Zemeng Ma, Xiaoyao Hao, Shuang Qu, Quanli Zhang, Jiajing Luo, Hongyan Li, Jinyu Liu, Wenwen Dai, Jun Li, Shouyong Gu, Dihan Zhu, Mingjiu Chen, Ke Zen

Journal for ImmunoTherapy of Cancer Apr 2025, 13 (4) e010580; DOI: 10.1136/jitc-2024-010580
Inhibition of stromal MAOA leading activation of WNT5A enhance prostate cancer immunotherapy by involving the transition of cancer-associated fibroblasts
Zhite Zhao, Yaohua Hu, Hui Li, Tong Lu, Xinglin He, Yifan Ma, Minli Huang, Mengyao Li, Lijun Yang, Changhong Shi

Journal for ImmunoTherapy of Cancer Mar 2025, 13 (3) e010555; DOI: 10.1136/jitc-2024-010555
Microbial Ecosystem Therapeutics 4 (MET4) elicits treatment-specific IgG responses associated with changes in gut microbiota in immune checkpoint inhibitor recipients with advanced solid tumors
Matthew K Wong, Giselle M Boukhaled, Eric Armstrong, Rachel Liu, Alya A Heirali, Noelle R Yee, Jinny Tsang, Pavlina Spiliopoulou, Pierre H H Schneeberger, Ben X Wang, Kyla Cochrane, Keith Sherriff, Emma Allen-Vercoe, Lillian L Siu, Anna Spreafico, Bryan Coburn

Journal for ImmunoTherapy of Cancer Mar 2025, 13 (3) e010681; DOI: 10.1136/jitc-2024-010681

Main menu

Immunotherapy Biomarkers

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Immunotherapy Biomarkers

Pages